Publication:
Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-alpha.

dc.contributor.authorMontes de Oca-Arjona, M
dc.contributor.authorPérez-Cano, R
dc.contributor.authorGarcia-Juárez, R
dc.contributor.authorMartín-Aspas, A
dc.contributor.authorFernández-Gutiérrez del Alamo, C
dc.contributor.authorGirón-González, J A
dc.contributor.authoraffiliation[Montes de Oca-Arjona, M; Pérez-Cano, R; García-Juarez, R; Martín-Aspas, A; Girón-Gonzáez, JA] Internal Medicine Services, Hospital Universitario Puerta del Mar, Cádiz, Spain. [Fernández-Gutiérrez del Álamo, C] Microbiology Services, Hospital Universitario Puerta del Mar, Cádiz, Spain.es
dc.date.accessioned2012-12-10T10:22:49Z
dc.date.available2012-12-10T10:22:49Z
dc.date.issued2006-04
dc.descriptionThis is a copy of an article published in the AIDS Research and Human Retroviruses © 2011 [copyright Mary Ann Liebert, Inc.]; AIDS Research and Human Retroviruses is available online at: http://online.liebertpub.com. Comparative Study; Journal Article;es
dc.description.abstractThe changes in nutritional parameters and adipocytokines after structured intermittent interruption of highly active antiretroviral treatment of patients with chronic HIV infection are analyzed. Twenty-seven patients with chronic HIV infection (median CD4+ T cell count/microl: nadir, 394; at the beginning of structured interruptions, 1041; HIV viral load: nadir, 41,521 copies/ml; at the beginning of structured interruptions <50 copies/ml; median time of previous treatment: 60 months) were evaluated during three cycles of intermittent interruptions of therapy (8 weeks on/4 weeks off). CD4+ T cell count, HIV viral load, anthropometric measures, and serum concentrations of triglycerides, cholesterol, leptin, and tumor necrosis factor and its soluble receptors I and II were determined. After the three cycles of intermittent interruptions of therapy, no significant differences in CD4+ T cell count/microl, viral load, or serum concentrations of cholesterol or triglycerides with reference to baseline values were found. A near-significant higher fatty mass (skinfold thicknesses, at the end, 121 mm, at the beginning, 100 mm, p = 0.100), combined with a significant increase of concentration of leptin (1.5 vs. 4.7 ng/ml, p = 0,044), as well as a decrease in serum concentrations of soluble receptors of tumor necrosis factor (TNFRI, 104 vs. 73 pg/ml, p = 0.022; TNFRII 253 vs. 195 pg/ml, p = 0.098) were detected. Structured intermittent interruption of highly active antiretroviral treatment of patients with chronic HIV infection induces a valuable positive modification in markers of lipid turnover and adipose tissue mass.es
dc.description.versionYeses
dc.identifier.citationMontes de Oca-Arjona M, Pérez-Cano R, Garcia-Juárez R, Martín-Aspas A, Fernández-Gutiérrez del Alamo C, Girón-González JA. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha. AIDS Res. Hum. Retroviruses. 2006 ; 22(4):307-14es
dc.identifier.doi10.1089/aid.2006.22.307
dc.identifier.essn1931-8405
dc.identifier.issn0889-2229
dc.identifier.pmid16623632
dc.identifier.urihttp://hdl.handle.net/10668/696
dc.journal.titleAIDS research and human retroviruses
dc.language.isoen
dc.publisherMary Ann Liebert Inces
dc.relation.publisherversionhttp://online.liebertpub.com/doi/abs/10.1089/aid.2006.22.307es
dc.rights.accessRightsopen access
dc.subjectRNA, Virales
dc.subjectReceptors, Leptines
dc.subjectReceptors, Tumor Necrosis Factor, Type Ies
dc.subjectReceptors, Tumor Necrosis Factor, Type IIes
dc.subjectTriglycerideses
dc.subjectTumor Necrosis Factor-alphaes
dc.subjectLeptin receptor, humanes
dc.subjectCholesteroles
dc.subjectLeptines
dc.subjectARN Virales
dc.subjectReceptores Tipo I de Factores de Necrosis Tumorales
dc.subjectReceptores de Leptinaes
dc.subjectReceptores Tipo II del Factor de Necrosis Tumorales
dc.subjectTriglicéridoses
dc.subjectFactor de Necrosis Tumoral alfaes
dc.subjectLeptinaes
dc.subjectColesteroles
dc.subjectReceptores de leptina, humanoses
dc.subjectRecuento de Linfocito CD4es
dc.subjectEstudios de Casos y Controleses
dc.subjectLinfocitos T CD4-Positivoses
dc.subjectEnfermedad crónicaes
dc.subjectGrosor de Pliegues Cutáneoes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antiretroviral Therapy, Highly Activees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count::Lymphocyte Count::CD4 Lymphocyte Countes
dc.subject.meshMedical Subject Headings::Anatomy::Hemic and Immune Systems::Blood::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocyteses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studieses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholesteroles
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Diseasees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Schedulees
dc.subject.meshMedical Subject Headings::Check Tags::Femalees
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infectionses
dc.subject.meshMedical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1es
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Adipokines::Leptines
dc.subject.meshMedical Subject Headings::Check Tags::Malees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Virales
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Adipokine::Receptors, Leptines
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Receptors, Tumor Necrosis Factor, Type IIes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD::Receptors, Tumor Necrosis Factor, Type IIes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Weights and Measures::Reference Standardses
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Skinfold Thicknesses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcomees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Lipids::Glycerides::Triglycerideses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alphaes
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Microbiological Phenomena::Virus Physiological Phenomena::Viral Loades
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adultes
dc.titleStructured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-alpha.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MontesdeOca_StructuredIntermittent.pdf
Size:
181.96 KB
Format:
Adobe Portable Document Format
Description:
Artículo publicado